Loading...
Market
How many additional patients will achieve 20/20 vision in LSCD trials by end of 2025?
2
Resolution / Starting Odds
0-5 patients • 25%
6-10 patients • 25%
11-15 patients • 25%
More than 15 patients • 25%
Results from subsequent clinical trials reported in scientific publications or press releases
Story
World-First Stem-Cell Treatment Restores Vision to 20/20 for Four Patients with Limbal Stem Cell Deficiency in Japan
Nov 8, 2024, 09:42 PM
A groundbreaking treatment using corneal epithelial cell sheets derived from human induced pluripotent stem cells (iPSCs) has restored vision in patients with limbal stem cell deficiency (LSCD). This world-first procedure was conducted in Japan as part of a single-arm, open-label, first-in-human interventional study. Four individuals with damaged corneas received the stem-cell transplants, and initial results indicate that the treatment is safe, although further testing in larger trials is necessary. Notably, one patient, previously legally blind, has achieved better than 20/20 vision following the procedure. The study highlights the potential of stem-cell therapies in restoring vision and addressing severe ocular conditions.
View original story
Similar markets
0-10 patients • 25%
11-20 patients • 25%
21-30 patients • 25%
More than 30 patients • 25%
0-25% • 25%
26-50% • 25%
51-75% • 25%
76-100% • 25%
0-4 • 25%
5-9 • 25%
10-14 • 25%
15 or more • 25%
Below 80% • 25%
80% to 85% • 25%
85% to 90% • 25%
Above 90% • 25%
Europe • 25%
Asia • 25%
South America • 25%
No expansion • 25%
Confirms significant risk • 25%
No significant risk found • 25%
Inconclusive results • 25%
Study retracted • 25%
Japan • 25%
USA • 25%
EU • 25%
Other • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
0-10 • 25%
11-50 • 25%
51-100 • 25%
More than 100 • 25%
Less than 50% • 25%
50% - 60% • 25%
60% - 70% • 25%
More than 70% • 25%
Less than 500 • 25%
500-1000 • 25%
1001-2000 • 25%
More than 2000 • 25%